Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy by Xia Liu, Emily Shaw, Fusheng Si, Guangyong Peng, Yan Tao, Feiya Ma, David Bagley, Yuanqin Zhang

“…Therefore, a better understanding of the molecular mechanism responsible for T cell senescence in the TME and development of novel strategies to prevent effector T cell senescence are urgently needed for cancer immunotherapy.Methods Senescent T cell populations in the TMEs in mouse lung cancer, breast cancer, and melanoma tumor models were evaluated. …”
Get full text

Toll-Like Receptor 4 Activation in Cancer Progression and Therapy by Alja Oblak, Roman Jerala

“…Cancer immunotherapy has been the focus of intense research since the late 19th century when Coley observed that bacterial components can contribute to cancer regression by eliciting an antitumor immune response. …”
Get full text

The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer by Si Chen, Caihong Yao, Na Tian, Chunying Zhang, Yuemei Chen, Xuting Wang, Yue Jiang, Tonghao Zhang, Tingting Zeng, Yali Song

“…Notable impacts on the immune microenvironment include changes in immune cell function and the regulation of immune checkpoints, offering insights into potential targets for cancer immunotherapy. Discussion This study highlights the complex relationship between chronic infections and cancer development, presenting new opportunities for cancer immunotherapy by understanding their effects on the immune microenvironment. …”
Get full text

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care by Drew M Pardoll, Suzanne L Topalian

Get full text

Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase by Takeshi Iwasaki, Takeshi Iwasaki, Hajime Yoshifuji, Koji Kitagori, Shuji Sumitomo, Shuji Akizuki, Ran Nakashima, Hideaki Tsuji, Ryosuke Hiwa, Mirei Shirakashi, Kosaku Murakami, Akira Onishi, Hideo Onizawa, Masao Tanaka, Fumihiko Matsuda, Akio Morinobu, Koichiro Ohmura, Koichiro Ohmura

Get full text

Exosomes, their sources, and possible uses in cancer therapy in the era of personalized medicine by Tomas Zemanek, Lubos Danisovic, Andreas Nicodemou

Get full text

New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function by Filip Lewandowski, Paulina Niedźwiedzka-Rystwej

“…Additionally, newly identified cytotoxic T-cell subsets, such as CD8 + CD39 + and CD8 + CD28 + cells, demonstrate unique effector properties with potential therapeutic applications in cancer immunotherapy. Furthermore, the discovery of CD20 + T cells challenges traditional views, offering new avenues for immunotherapy in cancer, autoimmune disorders, and infectious diseases. …”
Get full text

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study by Prashasti Agrawal, MD, Michael Offin, MD, Victoria Lai, MD, Michelle S. Ginsberg, MD, Prasad S. Adusumilli, MD, FACS, Valerie W. Rusch, MD, Jennifer L. Sauter, MD, Teresa Ho, BS, Phillip Wong, PhD, Marjorie G. Zauderer, MD

Get full text

Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches by Carmine D'Amico, Manlio Fusciello, Firas Hamdan, Federica D'Alessio, Paolo Bottega, Milda Saklauskaite, Salvatore Russo, Justin Cerioni, Khalil Elbadri, Marianna Kemell, Jouni Hirvonen, Vincenzo Cerullo, Hélder A. Santos

“…Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. …”
Get full text

Multiple Factors Determine the Oncolytic or Carcinogenic Effects of TLRs Activation in Cancer by Yingxiang Yang, Chengyue Jin, Anthony Yeo, Bo Jin

“…This mechanism is employed in cancer immunotherapy. Using TLR ligands as adjuvants induces upregulation of costimulatory signals which in turn activates a cytotoxic leukocyte response against cancer cells. …”
Get full text

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination by Mathias Vormehr, Barbara Schrörs, Sebastian Boegel, Martin Löwer, Özlem Türeci, Ugur Sahin

“…Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. …”
Get full text

Ocular Melanoma Metastasizing to Intra-Abdominal Lymph Nodes by David Aranovich, Karen Meir, Michal M. Lotem, Liat Appelbaum, Hadar Merhav

Get full text

tRNA-derived small RNAs: their role in the mechanisms, biomarkers, and therapeutic strategies of colorectal cancer by Bo Zhang, Yanru Pan, Zhe Li, Kefeng Hu

“…Consequently, future research should focus on elucidating the clinical significance of tsRNAs concerning base modifications, TIME regulation, cancer immunotherapy, and NPs delivery systems to facilitate their clinical translation.…”
Get full text

Helicobacter pylori and gastric cancer: mechanisms and new perspectives by Yantao Duan, Yonghu Xu, Yi Dou, Dazhi Xu

“…Emerging evidence also suggests the effect of H. pylori on the tumor microenvironment and its possible implications for cancer immunotherapy. This review synthesizes the current knowledge and identifies gaps that warrant further investigation. …”
Get full text

Branched-chain amino acids and specific phosphatidylinositols are plasma metabolite pairs associated with menstrual pain severity by Atsushi Sato, Kanako Yuyama, Yuko Ichiba, Yasushi Kakizawa, Yuki Sugiura

Get full text

A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy by Manqing Peng, Xiaofang Lu, Junshuang Guo, Xiangli Yin, Jing Zhang, Xin Li, Yizhou Zou

“…The dual role of these checkpoints in immune regulation presents novel opportunities for advancing cancer immunotherapy and developing new strategies for managing autoimmune conditions.…”
Get full text

Neoantigen mRNA vaccines and A2A receptor antagonism: A strategy to enhance T cell immunity by Saber Imani, Parham Jabbarzadeh Kaboli, Ali Babaeizad, Mazaher Maghsoudloo

“…This synergy represents significant progress in cancer immunotherapy, advancing the potential for personalized neoantigen therapies.…”
Get full text

Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge by Bairu Shen, Zi Guo, Peng Huang, Minghua Tan, Xiaoshen Zhang, Siyao Lin, Changshan Song, Jiaqing Wang, Minqian Huang

“…We collected retrospective studies on “post-transplantation, cancer, immunotherapy, and vascular targeting therapy” in Embase, Wanfang database, Cochrane Library, VIP databases, CNKI, and PubMed, and the case data were organized and analyzed. …”
Get full text

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer by Beatriz Ramos, Dakota Rogers

“…Additionally, nanovaccine strategies incorporating tumor-associated antigens and immune adjuvants show potential for personalized cancer immunotherapy. Here, we discuss the immune landscape of bladder cancer, explore the emerging immunotherapies being used as bladder cancer treatment, and discuss the advantages of using nanoparticles as carriers of immunotherapies against bladder cancer. …”
Get full text

Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis by Zihao Chen, Xin Chen, Dingchao Li, Jingang jian, Chang Yao, Xuedong Wei, Jianquan Hou

Get full text